Know Labs CEO Phil Bosua Presents Overview of the Company's Technology and Product Strategy

Business Wire 18-Dec-2018 9:00 AM

Know Labs, Inc. (OTCQB:KNWN) – a provider of diagnostic solutions, released today a video presentation highlighting the Know Labs non-invasive Bio-RFID™ technology and the product pathway for the company's UBAND™ wearable. In the video presentation Company CEO Phil Bosua discusses the Company's breakthrough technology, details the product strategy for deploying the technology in to the marketplace and addresses the significant scope of the market opportunity for Know Labs. The presentation also highlights a comparison of the Know Labs UBAND Bio-RFID technology with an industry leading continuous glucose monitor from Abbott Laboratories (NYSE:ABT) and Dexcom (NASDAQ:DXCM).

The transcript of Phil Bosua's presentation in the video states in part:

"At Know Labs we like to think of ourselves as a non-invasive biotech company. This industry doesn't exist yet, but we think our new technology will be the catalyst for the creation of this industry as the future on personal health because we invented the world's first non-invasive blood glucose monitoring platform. This is a really big deal. We call it Bio-RFID which stands for radio frequency identification in biology. It's a brand-new invention that's on par with the X-ray machine because it also measures other things in the body - not just blood glucose. Truly innovative companies are very rare and we think Know Labs is one of these companies."

Link to video: https://www.youtube.com/watch?v=NkPMc4ZorwQ&feature=youtu.be

Know Labs, Inc. is not affiliated with Abbott Laboratories or Dexcom.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares currently trade under the stock symbol "KNWN." The company's technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company's website at www.knowlabs.co

Safe Harbor Statement

This video at the link above and this release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words may, would, will, expect, estimate, can, believe, potential and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181218005159/en/